信得科技SINDER品牌怎么样 申请店铺

我要投票 信得科技SINDER在兽药行业中的票数:48 更新时间:2024-12-27
信得科技SINDER是哪个国家的品牌?「信得科技SINDER」是 山东信得科技股份有限公司 旗下著名品牌。该品牌发源于山东省潍坊市,在1999年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
信得科技SINDER怎么样

山东信得科技股份有限公司,成立于1999年,山东省著名商标,集生物制品/生化制药/兽药制剂/饲料添加剂及兽药原料药的研发、生产和销售于一体的高新技术企业集团


山东信得科技股份有限公司的前身诸城信得药业有限公司成立于1999年4月,公司自成立以来,始终坚持“坚定不移地增加客户价值”的核心理念,实现了持续、健康发展。现已发展成为集研发、生产和销售于一体的企业集团。

目前拥有生物制品、生化制药、兽药制剂、饲料添加剂及兽药原料药五个产品线,集团由山东信得科技股份有限公司,山东信得动物疫苗有限公司、青岛信得药业有限公司、四川华西动物药业有限公司、北京信得威特科技有限公司组成。

集团拥有四个生产基地,其中坐落在诸城开发区的信得生物工业园拥有两个生化制药车间、三个兽药制剂车间、一个原料药合成车间、一个中药提取萃取车间、一个生物酶发酵车间及相应配套设施;北京信得生物制品工厂拥有六条生产线,是国内品种较全的兽用生物制品工厂;山东信得疫苗公司的工厂主要生产高致病性禽流感疫苗;四川华西工厂主要以生产猪药为主,拥有水针、粉针、口服液、中药等多条生产线。

集团拥有两个技术中心,还拥有三个P2实验室、三个国家认证的动物房;P3实验室正在建设之中。

集团研发团队拥有博士、硕士100余名,除了加强自身研发团队建设外,公司联合中国农大、中国农科院、中国兽药监察所、哈兽研、华南农大、青岛农大以及多家兽药企业成立由信得集团担任理事长的中国动物保健产业研发创新联盟,建立了更大的技术创新平台,已经开展的技术合作三十余项;集团还与澳大利亚生物资源公司、法国维克公司、台湾动物疫苗研究所等国际动保公司及研究机构建立了合作关系。

除了在新产品开发上投入很大的资源外,集团还投入巨大的人力物力于动物疫病控制的研究上,集团技术中心设立了猪病和禽病两个实验室,每天对来自全国的病料进行病原分离分析;综合全国的动物疫情设计疾病控制方案,并进行大量的临床试验,以筛选较佳方案;集团还与中国农大赵继勋教授及其研究团队建立了合作关系,跟踪各种传染性疾病的毒株变异,及时改造疫苗毒株。

集团根据服务目标客户设立了八个业务部,实现了技术服务的专业化。八个业务部分别为家禽业务部、家畜业务部、进口疫苗业务部、自产疫苗业务部、国家强制免疫产品业务部、饲料添加剂业务部、原料药业务部、国际业务部。

公司一直把为养殖业提供疾病控制方案作为重要的技术服务支持手段,同时还为合作伙伴提供技术培训、管理咨询等服务支持,帮助合作伙伴做大做强。由于持续的坚持为客户创造价值,信得的品牌得到了养殖业客户的认可。

作为一家富有社会责任感的企业,信得先后为希望工程、抗震救灾等社会公益事业累计捐款、捐物数百万元。


Shandong Xinde Technology Co., Ltd., founded in 1999, is a famous trademark of Shandong Province. Zhucheng Xinde Pharmaceutical Co., Ltd., the predecessor of Shandong Xinde Technology Co., Ltd., was founded in April 1999. Since its establishment, the company has always been Adhering to the core concept of "unswervingly increasing customer value", we have achieved sustained and healthy development. Now it has developed into an enterprise group integrating R & D, production and sales. At present, the group has five product lines of biological products, biochemical pharmaceuticals, veterinary pharmaceutical preparations, feed additives and veterinary drug APIs. The group is composed of Shandong Xinde Technology Co., Ltd., Shandong Xinde animal vaccine Co., Ltd., Qingdao Xinde Pharmaceutical Co., Ltd., Sichuan Huaxi Animal Pharmaceutical Co., Ltd. and Beijing Xinde Weite Technology Co., Ltd. The group has four production bases, including two biochemical pharmaceutical workshops, three veterinary medicine preparation workshops, one API synthesis workshop, one traditional Chinese medicine extraction workshop, one biological enzyme fermentation workshop and corresponding supporting facilities in Xinde bio Industrial Park, which is located in Zhucheng Development Zone; Beijing Xinde bio product factory has six production lines, which are full range of domestic veterinary products Products factory; Shandong Xinde vaccine company's factory mainly produces highly pathogenic avian influenza vaccine; Sichuan Huaxi factory mainly produces swine medicine, with multiple production lines such as water injection, powder injection, oral liquid and traditional Chinese medicine. The group has two technology centers, three P2 laboratories and three national certified animal houses; P3 laboratory is under construction. The R & D team of the group has more than 100 doctors and masters. In addition to strengthening the construction of its own R & D team, the company, together with China Agricultural University, Chinese Academy of Agricultural Sciences, China Veterinary Drug Supervision Institute, Harbin Veterinary Research Institute, South China Agricultural University, Qingdao Agricultural University and a number of veterinary drug enterprises, has established the R & D and innovation alliance of China's animal health industry, with the director of cred group, and established a larger technological innovation platform, More than 30 technical cooperation projects have been carried out; the group has also established cooperation relations with international animal protection companies and research institutions such as Australia biological resources company, France Vick company, Taiwan Animal Vaccine Research Institute, etc. In addition to investing a lot of resources in the development of new products, the group has also invested a lot of manpower and material resources in the research of animal epidemic control. The group technology center has set up two laboratories of pig disease and poultry disease, which carry out pathogen separation and Analysis on disease materials from all over the country every day. The disease control scheme is designed based on the national animal epidemic situation, and a large number of clinical trials are carried out to screen the better prescription The group also established a cooperative relationship with Professor Zhao Jixun and his research team of China Agricultural University to track the strain variation of various infectious diseases and timely modify the vaccine strain. The group has set up eight business departments according to the service target customers, realizing the specialization of technical services. Eight business departments are poultry business department, livestock business department, imported vaccine business department, self produced vaccine business department, national compulsory immunization product business department, feed additive business department, API business department and international business department. The company has always regarded providing disease control programs for the breeding industry as an important technical service support means, and also provided technical training, management consulting and other service support for partners to help them grow bigger and stronger. As a result of continuous adherence to create value for customers, the trusted brand has been recognized by the breeding industry customers. As an enterprise with a sense of social responsibility, trust has donated millions of yuan to hope project, earthquake relief and other social public welfare undertakings.

本文链接: https://brand.waitui.com/10040f1eb.html 联系电话:800-860-3368,400-817-6686

千城特选小程序码

7×24h 快讯

马斯克自曝转用礼来减肥药:效果优于诺和诺德竞品,副作用更少

埃隆·马斯克周三在社交媒体平台X上透露,他正在使用礼来公司的 Mounjaro来减肥。马斯克在X上发布了一张他打扮成圣诞老人的照片,照片中他站在一棵圣诞树旁,并配文“Ozempic圣诞老人”。马斯克在另一条帖子中表示:“就像可卡因熊(Cocaine Bear),不过这是圣诞老人和Ozempic的组合。”马斯克随后在多条帖子中证实自己确实在使用类似Ozempic的药物来减重。Ozempic是诺和诺德旗下的糖尿病药物。

2小时前

相对吸引力上升,港股红利资产受关注

日前,平安港股通红利优选发布公告称,将原定募集时间截止日2024年12月20日,延长至2024年12月25日。存量红利产品方面,国联安新蓝筹红利一年定开于近期宣布清盘,截至三季度末,该基金规模仅有0.57亿元。业内人士表示,由于红利产品此前密集发行,同质化问题凸显,同类产品竞争激烈,是导致上述现象的主要原因。在投资机会上,港股红利指数具有较好的收益稳定性,近期可以积极关注相关品种。(中证网)

2小时前

看好明年A股,外资公募积极“上新”

2024年临近尾声,外资公募正积极“上新”,为明年的A股投资做准备。富达基金和贝莱德基金近日发布公告称,公司旗下各有一只权益类产品将于明年1月发行。此外,富达低碳成长混合已于今年12月底成立。多家外资机构表示,在企业盈利复苏、股票估值合理、政策工具充足等利好因素的支撑下,明年的A股市场将为主动管理提供有利的投资环境。(上证报)

2小时前

国泰君安:OpenAI提升用户体验,o3模型创新突破

36氪获悉,国泰君安研报表示,OpenAI 12 days发布会最后四天发布了o1 API、o3等最新功能。o1模型通过增强API功能(如函数调用、结构化输出和视觉输入),大幅提升了开发者的效率和应用场景的多样性;o3系列模型则在编码、数学和科学推理等领域展现出接近或超越人类专家的能力,同时通过灵活的推理强度设置,显著降低了使用成本。重点关注以下赛道:AI开发工具与平台(如API服务和SDK支持);AI推理与高性能计算,以及AI安全对齐技术产品。这些领域或将受益于OpenAI的技术突破而得到更多发展机遇。

2小时前

芬兰对涉嫌海底电缆断裂事件的油轮展开调查

芬兰警方26日说,芬兰执法部门正在对一艘油轮展开调查,该油轮可能与25日波罗的海海域连接芬兰和爱沙尼亚的一条海底电缆断裂事件有关。根据芬兰警方发布的新闻通报,海底电缆断裂发生在芬兰专属经济区内。芬兰政府26日在一份新闻公报中说,这一故障暂时不会对芬兰的电力系统构成威胁,短期内对电价的影响不大。(央视新闻)

2小时前

本页详细列出关于碧云天B.Y.T的品牌信息,含品牌所属公司介绍,碧云天B.Y.T所处行业的品牌地位及优势。
咨询